Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,733.55 +2,939.95 (+4.92%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Mersana Therapeutics, Inc. (MRSN)
After hours:
| Previous close | 3.3600 |
| Open | 3.5200 |
| Bid | 3.4400 x 1100 |
| Ask | 3.4700 x 700 |
| Day's range | 3.4200 - 3.6300 |
| 52-week range | 0.8010 - 9.6200 |
| Volume | |
| Avg. volume | 2,246,400 |
| Market cap | 423.369M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4800 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.71 |
GlobeNewswireMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock
- GlobeNewswire
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eas
ZacksStrength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
